The megaround re­bound: Pri­vate biotechs rack up $100M+ fi­nanc­ings

Big mon­ey is back.

Over the past 12 weeks, biotech star­tups have raised $100 mil­lion-plus megarounds from ven­ture cap­i­tal­ists at a pace that could ap­proach the mar­ket’s peak three years ago.

This week alone, three star­tups an­nounced ma­jor new fi­nanc­ings. En­grail, a neu­ro­science com­pa­ny in Phase 2, took in $157 mil­lion. Two pre­clin­i­cal biotechs, T cell en­gager play­er Clasp and in vi­vo CAR-T start­up Cap­stan, land­ed $150 mil­lion and $175 mil­lion, re­spec­tive­ly.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.